Call Options

23 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Jul 18, 2023

SELL
$11.12 - $22.2 $16,680 - $33,300
-1,500 Reduced 19.74%
6,100 $0
Q1 2023

May 01, 2023

SELL
$18.7 - $23.07 $1.01 Million - $1.25 Million
-54,100 Reduced 87.68%
7,600 $0
Q4 2022

Feb 07, 2023

BUY
$18.12 - $27.32 $224,688 - $338,768
12,400 Added 25.15%
61,700 $29,000
Q3 2022

Oct 25, 2022

SELL
$16.98 - $25.54 $73,014 - $109,822
-4,300 Reduced 8.02%
49,300 $31,000
Q2 2022

Aug 04, 2022

BUY
$13.15 - $20.45 $394,500 - $613,500
30,000 Added 127.12%
53,600 $58,000
Q1 2022

Apr 14, 2022

SELL
$14.54 - $21.5 $334,420 - $494,500
-23,000 Reduced 49.36%
23,600 $13,000
Q4 2021

Jan 18, 2022

SELL
$20.24 - $36.01 $95,127 - $169,247
-4,700 Reduced 9.16%
46,600 $21,000
Q3 2021

Oct 26, 2021

BUY
$26.01 - $38.22 $1.21 Million - $1.78 Million
46,600 Added 991.49%
51,300 $143,000
Q1 2021

Apr 26, 2021

BUY
$29.24 - $42.03 $116,960 - $168,120
4,000 Added 571.43%
4,700 $7,000
Q4 2020

Jan 21, 2021

SELL
$35.35 - $50.67 $60,095 - $86,139
-1,700 Reduced 70.83%
700 $0
Q3 2020

Oct 27, 2020

BUY
$35.98 - $47.66 $82,754 - $109,617
2,300 Added 2300.0%
2,400 $4,000
Q2 2020

Jul 22, 2020

SELL
$45.06 - $67.74 $72,096 - $108,383
-1,600 Reduced 94.12%
100 $0
Q1 2020

May 07, 2020

SELL
$40.01 - $73.97 $216,054 - $399,438
-5,400 Reduced 76.06%
1,700 $0
Q4 2019

Feb 06, 2020

SELL
$37.13 - $74.62 $768,591 - $1.54 Million
-20,700 Reduced 74.46%
7,100 $16,000
Q3 2019

Oct 28, 2019

BUY
$39.36 - $76.8 $283,392 - $552,960
7,200 Added 34.95%
27,800 $33,000
Q2 2019

Aug 09, 2019

BUY
$52.76 - $82.19 $575,084 - $895,871
10,900 Added 112.37%
20,600 $300,000
Q1 2019

May 10, 2019

BUY
$27.39 - $68.41 $167,079 - $417,301
6,100 Added 169.44%
9,700 $122,000
Q4 2018

Feb 05, 2019

SELL
$22.8 - $33.93 $221,160 - $329,121
-9,700 Reduced 72.93%
3,600 $12,000
Q3 2018

Nov 07, 2018

SELL
$29.75 - $43.08 $116,025 - $168,012
-3,900 Reduced 22.67%
13,300 $15,000
Q2 2018

Aug 10, 2018

BUY
$21.96 - $39.94 $296,460 - $539,190
13,500 Added 364.86%
17,200 $285,000
Q1 2018

May 11, 2018

BUY
$17.1 - $26.61 $49,590 - $77,169
2,900 Added 362.5%
3,700 $28,000
Q4 2017

Jan 17, 2018

BUY
$9.47 - $19.59 $3,788 - $7,836
400 Added 100.0%
800 $4,000
Q3 2017

Oct 17, 2017

BUY
$7.7 - $9.6 $3,080 - $3,840
400
400 $0

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.